OverviewSuggest Edit
Pfenex is a clinical-stage biotechnology company developing and commercializing high-value and difficult to manufacture proteins. The Company has developed a high-quality protein production and bioanalytic technology platform approach that allows them to create biosimilars in a highly efficient manner.
Pfenex's patented protein production platform, Pfenex Expression Technology, enables its ability to produce complex proteins relative to other systems. With advantages including quality, stability, solubility, and purity, Pfenex reduces production and development costs that enable the rapid delivery of protein products into clinical development and commercialization.
| Type | Public | |
| Founded | 2009 | |
| HQ | San Diego, US | Map |
| Website | pfenex.com | |
| Employee Ratings | More |
Recent NewsAll News
- Thinking about buying stock in Aurora Cannabis, Coca-Cola, Match Group, Pfenex, or RingCentral?
- Pfenex Receives U.S. FDA Approval for PF708 to Treat Osteoporosis
- Pfenex to Participate at the William Blair Late-Stage Therapeutics Conference
- Pfenex Reports Fourth Quarter and Full Year 2018 Results and Provides Business Update
Key People/Management at Pfenex
Patrick Lucy
Albert Hansen
James C. Gale
Eef Schimmelpennink
Pfenex Office Locations
Pfenex Financials and Metrics
Pfenex Revenue
| USD | |
|---|---|
Revenue (Q2, 2019) | 2.8m |
Gross profit (Q2, 2019) | 1.7m |
Gross profit margin (Q2, 2019), % | 60.1% |
Net income (Q2, 2019) | (7.6m) |
EBIT (Q2, 2019) | (7.7m) |
Market capitalization (11-Oct-2019) | 280.6m |
Closing stock price (11-Oct-2019) | 8.9 |
Cash (30-Jun-2019) | 41.6m |
EV | 239.3m |
| USD | Q2, 2014 | Q3, 2014 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 3.3m | 2.8m | 2.3m | 2.1m | 2.8m | 3.1m | 48.8m | 2.8m | 3.0m | 5.0m | 3.7m | 4.2m | 3.6m | 10.4m | 2.8m |
Cost of goods sold | 2.5m | 1.6m | 921.0k | 682.0k | 1.3m | 1.4m | 1.3m | 810.0k | 905.0k | 1.8m | 1.5m | 924.0k | 1.5m | 1.6m | 1.1m |
Gross profit | 722.0k | 1.2m | 1.4m | 1.4m | 1.5m | 1.7m | 47.5m | 2.0m | 2.1m | 3.3m | 2.2m | 3.3m | 2.1m | 8.8m | 1.7m |
Gross profit Margin, % | 22% | 44% | 60% | 67% | 54% | 54% | 97% | 71% | 70% | 65% | 59% | 78% | 59% | 85% | 60% |
| USD | Q2, 2014 | Q3, 2014 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 3.9m | 51.5m | 123.0m | 115.9m | 96.5m | 89.6m | 93.6m | 70.2m | 59.9m | 48.4m | 47.1m | 80.2m | 67.8m | 45.8m | 41.6m |
Inventories | 31.0k | 25.0k | |||||||||||||
Current Assets | 10.7m | 57.6m | 130.5m | 122.6m | 102.1m | 94.2m | 97.4m | 74.2m | 63.6m | 54.3m | 50.3m | 83.7m | 71.9m | 54.7m | 46.9m |
PP&E | 2.1m | 2.0m | 2.7m | 3.1m | 4.1m | 4.4m | 5.1m | 5.5m | 6.3m | 7.3m | 7.4m | 7.4m | 7.5m | 7.6m | 7.5m |
| USD | Q2, 2014 | Q3, 2014 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (3.7m) | (6.2m) | (12.0m) | (19.5m) | (8.2m) | (18.4m) | 16.1m | (10.0m) | (22.4m) | (31.2m) | (11.0m) | (22.1m) | (32.8m) | (3.7m) | (11.3m) |
Depreciation and Amortization | 233.0k | 348.0k | 257.0k | 394.0k | 149.0k | 309.0k | 488.0k | 187.0k | 391.0k | 619.0k | 274.0k | 558.0k | 849.0k | 311.0k | 629.0k |
Inventories | 8.0k | 2.0k | (8.0k) | (2.0k) | |||||||||||
Accounts Payable | (677.0k) | (324.0k) | 598.0k | 273.0k | 202.0k | 562.0k | 1.0m | (79.0k) | 475.0k | 307.0k | (333.0k) | 630.0k | (560.0k) | (822.0k) | (1.5m) |
| USD | Y, 2019 |
|---|---|
EV/EBIT | -31.1 x |
EV/CFO | -16.8 x |
Financial Leverage | 1.2 x |
Pfenex Online and Social Media Presence
4.23k Twitter followers
Pfenex has 4.23k Twitter Followers. The number of followers has increased 0.1% month over month and increased 0.3% quarter over quarter
Pfenex's Trends
Twitter Engagement Stats for @pfenex
689
Tweets
208
Following
4.2k
Followers
3
Tweets last 30 days
2
Avg. likes per Tweet
100%
Tweets with engagement
Pfenex News and Updates
Thinking about buying stock in Aurora Cannabis, Coca-Cola, Match Group, Pfenex, or RingCentral?
Pfenex Receives U.S. FDA Approval for PF708 to Treat Osteoporosis
Pfenex to Participate at the William Blair Late-Stage Therapeutics Conference
Pfenex Reports Fourth Quarter and Full Year 2018 Results and Provides Business Update
Pfenex Reports New Employment Inducement Award Under NYSE American Listing Rules
Pfenex to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
Pfenex Blogs
Pfenex Provides Update for PF708 Outside the United States
Pfenex to Present at the Cantor Healthcare Conference
Pfenex to Participate in the Oppenheimer Fall Summit
Pfenex Appoints Dr. Steve Kay to Scientific Advisory Board
Pfenex Frequently Asked Questions
When was Pfenex founded?
Pfenex was founded in 2009.
Who are Pfenex key executives?
Pfenex's key executives are Patrick Lucy, Albert Hansen and James C. Gale.
How many employees does Pfenex have?
Pfenex has 71 employees.
What is Pfenex revenue?
Latest Pfenex annual revenue is $14.9 m.
What is Pfenex revenue per employee?
Latest Pfenex revenue per employee is $209.3 k.
Who are Pfenex competitors?
Competitors of Pfenex include U.S. Stem Cell, Enanta Pharmaceuticals and Endologix.
Where is Pfenex headquarters?
Pfenex headquarters is located at 10790 Roselle St, San Diego.
Where are Pfenex offices?
Pfenex has an office in San Diego.
How many offices does Pfenex have?
Pfenex has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies